Total Valuation
ANI Pharmaceuticals has a market cap or net worth of €1.55B. The enterprise value is €1.94K.
Market Cap€1.55B
Enterprise Value€1.94K
Share Statistics
ANI Pharmaceuticals has 22,734,617 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding22,734,617
Owned by Insiders7.95%
Owned by Institutions1.78%
Financial Efficiency
ANI Pharmaceuticals’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is 5.63%.
Return on Equity (ROE)0.14
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)5.63%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee910.69K
Profits Per Employee80.76K
Employee Count970
Asset Turnover0.61
Inventory Turnover3.02
Valuation Ratios
The current PE Ratio of ANI Pharmaceuticals is 18.9. ANI Pharmaceuticals’s PEG ratio is -0.05.
PE Ratio18.9
PS Ratio1.79
PB Ratio2.93
Price to Fair Value2.93
Price to FCF10.49
Price to Operating Cash Flow7.78
PEG Ratio-0.05
Income Statement
In the last 12 months, ANI Pharmaceuticals had revenue of 883.37M and earned 78.34M in profits. Earnings per share was 3.50.
Revenue883.37M
Gross Profit450.64M
Operating Income81.23M
Pretax Income95.79M
Net Income78.34M
EBITDA207.27M
Earnings Per Share (EPS)3.50
Cash Flow
In the last 12 months, operating cash flow was 208.61M and capital expenditures -48.26M, giving a free cash flow of 160.35M billion.
Operating Cash Flow208.61M
Free Cash Flow160.35M
Free Cash Flow per Share7.05
Dividends & Yields
ANI Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.27
52-Week Price Change21.24%
50-Day Moving Average70.36
200-Day Moving Average69.53
Relative Strength Index (RSI)41.37
Average Volume (3m)0.00
Important Dates
ANI Pharmaceuticals upcoming earnings date is Aug 7, 2026, Before Open (Confirmed).
Last Earnings DateMay 8, 2026
Next Earnings DateAug 7, 2026
Ex-Dividend Date―
Financial Position
ANI Pharmaceuticals as a current ratio of 2.71, with Debt / Equity ratio of 58.29%
Current Ratio2.71
Quick Ratio2.19
Debt to Market Cap0.21
Net Debt to EBITDA0.19
Interest Coverage Ratio4.05
Taxes
In the past 12 months, ANI Pharmaceuticals has paid 17.45M in taxes.
Income Tax17.45M
Effective Tax Rate0.18
Enterprise Valuation
ANI Pharmaceuticals EV to EBITDA ratio is 7.83, with an EV/FCF ratio of 10.75.
EV to Sales1.84
EV to EBITDA7.83
EV to Free Cash Flow10.75
EV to Operating Cash Flow8.76
Balance Sheet
ANI Pharmaceuticals has €311.18M in cash and marketable securities with €327.76M in debt, giving a net cash position of -€16.59M billion.
Cash & Marketable Securities€311.18M
Total Debt€327.76M
Net Cash-€16.59M
Net Cash Per Share-€0.73
Tangible Book Value Per Share-€0.06
Margins
Gross margin is 65.94%, with operating margin of 9.20%, and net profit margin of 8.87%.
Gross Margin65.94%
Operating Margin9.20%
Pretax Margin10.84%
Net Profit Margin8.87%
EBITDA Margin23.46%
EBIT Margin13.11%
Analyst Forecast
The average price target for ANI Pharmaceuticals is €95.73, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€95.73
Price Target Upside39.76% Upside
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast26.61%
EPS Growth Forecast―